Ergea Healthcare Limited

Ergea Healthcare Ltd, based in London, UK, is a sizable holding company with an active status, having been incorporated fourteen years ago in December 2010. The company employs fifteen people and boasts significant assets of £15,350,035, generating a yearly revenue of £16,411,310. It’s managed by three directors and owned by Dws Alternatives Global Ltd, with a respectable Google rating of 4.0 based on one review. Ergea Healthcare is an irregular importer, specializing in optical and medical tools and devices, with the last import operation occurring just one month ago.

The company operates in the hospital activities industries and owns a subsidiary, Ergea Leeds Limited. It was previously known as Medipass Healthcare Limited. Its registered address is a real address, shared by only two other companies, suggesting a professional business location.

Financially, Ergea Healthcare shows a mixed picture. While current assets increased by a substantial 73% to £15,000,000, net losses deepened from -£180,000 to -£2,300,000. Bank borrowings surged by 2,400%, reaching £29,000, and cash reserves fell 30% to £28,000. Creditors decreased by 18%, suggesting better debt management. The company is classified as a large company, having met two of three criteria, with turnover exceeding £36 million and balance sheet total over £18 million. The lack of an auditor mentioned likely means the financial statements are unaudited.

The company's financial trends suggest it's facing challenges despite its size and revenue. It's possible the increased borrowing reflects investments in growth or acquisitions, but the deepening losses raise concerns. The company's irregular import activity, while not inherently negative, could indicate supply chain vulnerabilities or fluctuating demand.

Registered in England/Wales under the registration number 07463229, with a registered address at W1H 7QX, England, London, First Floor, 67 Upper Berkeley Street.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.